Wall Street analyst estimates for Kodiak Sciences Inc. (KOD): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Consensus price target
$104.40 (+6 % vs price $98.89)
between $61.00 and $126.00 · 6 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2028E | $375M | $263M – $624M | -$0.51 | 5 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 14 |
| Hold | 4 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 19 |
| Avg rating (−2 sell to +2 buy) | 0.68 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-1.06 | ||
| 2026-08-12 | $-1.05 | $-0.96 | -9.8% |
| 2026-05-07 | $-0.94 | $-0.93 | -1.1% |
| 2026-03-31 | $-1.04 | $-1.02 | -2.0% |
| 2025-11-13 | $-1.16 | $-1.07 | -8.4% |
| 2025-08-13 | $-1.03 | $-1.01 | -2.0% |
| 2025-05-14 | $-1.09 | $-0.89 | -22.5% |
| 2025-03-27 | $-0.84 | $-0.90 | +6.7% |
Valuation Ratios
| Price / Book | 101.37 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $257,000 | $549,000 | $490,000 | $911,000 | $4.2M | $8.7M | $11.0M | $25.9M | $26.7M | 0 |
| Gross Profit | -$257,000 | -$549,000 | -$490,000 | -$911,000 | -$4.2M | -$8.7M | -$11.0M | -$25.9M | -$26.7M | 0 |
| Research & Development | $14.1M | $22.0M | $18.8M | $37.5M | $107.4M | $217.3M | $267.6M | $206.3M | $126.1M | $182.4M |
| Selling, General & Admin | $3.1M | $3.5M | $7.6M | $10.8M | $24.4M | $41.0M | $62.8M | $71.0M | $34.0M | $52.0M |
| Operating Expenses | $17.2M | $25.5M | $26.4M | $48.3M | $131.8M | $258.3M | $330.4M | $251.4M | $160.1M | $234.4M |
| Operating Income | -$17.2M | -$25.5M | -$26.4M | -$49.2M | -$136.0M | -$267.1M | -$341.4M | -$277.3M | -$186.8M | -$234.4M |
| EBITDA | -$16.9M | -$26.2M | -$35.4M | -$46.4M | -$128.9M | -$258.3M | -$322.8M | -$234.5M | -$149.5M | -$203.6M |
| Interest Expense | $6,000 | $1.2M | $5.5M | $8,000 | $25,000 | $22,000 | $18,000 | $13,000 | 0 | 0 |
| Pre-tax Income | -$17.1M | -$27.9M | -$41.4M | -$47.4M | -$133.1M | -$267.0M | -$333.8M | -$260.5M | -$176.2M | -$230.0M |
| Income Tax | $31,000 | -$45,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$17.1M | -$27.9M | -$41.4M | -$47.4M | -$133.1M | -$267.0M | -$333.8M | -$260.5M | -$176.2M | -$230.0M |
| EPS | -$2.30 | -$1.05 | -$1.16 | -$1.23 | -$2.91 | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| EPS (Diluted) | -$2.30 | -$1.05 | -$1.16 | -$1.23 | -$2.91 | -$5.16 | -$6.39 | -$4.97 | -$3.35 | -$4.32 |
| Shares Outstanding (Diluted) | 7.4 M | 26.6 M | 35.9 M | 37.9 M | 45.7 M | 51.8 M | 52.2 M | 52.4 M | 52.6 M | 53.2 M |
Price
| Price | $98.89 (closing price, November 3, 2026) |
| Market Cap | $6.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: REGN · BLTE · BLCO · VRTX · 0QZU.L · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of KOD: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks